JP2011522897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522897A5 JP2011522897A5 JP2011513647A JP2011513647A JP2011522897A5 JP 2011522897 A5 JP2011522897 A5 JP 2011522897A5 JP 2011513647 A JP2011513647 A JP 2011513647A JP 2011513647 A JP2011513647 A JP 2011513647A JP 2011522897 A5 JP2011522897 A5 JP 2011522897A5
- Authority
- JP
- Japan
- Prior art keywords
- phentermine
- cancer
- formulated
- kit
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims 12
- 239000002552 dosage form Substances 0.000 claims 9
- 229960001277 phentermine hydrochloride Drugs 0.000 claims 7
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 claims 7
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 6
- 229960003562 phentermine Drugs 0.000 claims 6
- 229960004394 topiramate Drugs 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 5
- 238000013270 controlled release Methods 0.000 claims 5
- 235000020824 obesity Nutrition 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
- 150000003626 triacylglycerols Chemical class 0.000 claims 3
- 230000004580 weight loss Effects 0.000 claims 3
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010021024 Hypolipidaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000037093 Menstruation Disturbances Diseases 0.000 claims 1
- 206010027339 Menstruation irregular Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002787 Pregnancy Complications Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000004228 ovarian endometrial cancer Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000000689 peptic esophagitis Diseases 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 208000012113 pregnancy disease Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/135,953 US20090304789A1 (en) | 2008-06-09 | 2008-06-09 | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
| US12/135,953 | 2008-06-09 | ||
| PCT/US2009/046805 WO2009152190A1 (en) | 2008-06-09 | 2009-06-09 | Escalating dosing regimen for effecting weight loss and treating obesity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015102962A Division JP6077053B2 (ja) | 2008-06-09 | 2015-05-20 | 体重減少の達成および肥満症の治療のための漸増用量投与計画（ｅｓｃａｌａｔｉｎｇｄｏｓｉｎｇｒｅｇｉｍｅｎ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011522897A JP2011522897A (ja) | 2011-08-04 |
| JP2011522897A5 true JP2011522897A5 (enExample) | 2013-11-14 |
| JP5752595B2 JP5752595B2 (ja) | 2015-07-22 |
Family
ID=40863844
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513646A Pending JP2011522896A (ja) | 2008-06-09 | 2009-06-09 | 低用量トピラメート／フェンテルミン組成物およびその使用方法 |
| JP2011513647A Active JP5752595B2 (ja) | 2008-06-09 | 2009-06-09 | 体重減少の達成および肥満症の治療のための漸増用量投与計画（ｅｓｃａｌａｔｉｎｇｄｏｓｉｎｇｒｅｇｉｍｅｎ） |
| JP2015102962A Active JP6077053B2 (ja) | 2008-06-09 | 2015-05-20 | 体重減少の達成および肥満症の治療のための漸増用量投与計画（ｅｓｃａｌａｔｉｎｇｄｏｓｉｎｇｒｅｇｉｍｅｎ） |
| JP2015151088A Pending JP2016006085A (ja) | 2008-06-09 | 2015-07-30 | 低用量トピラメート／フェンテルミン組成物およびその使用方法 |
| JP2016246871A Active JP6214750B2 (ja) | 2008-06-09 | 2016-12-20 | 低用量トピラメート／フェンテルミン組成物およびその使用方法 |
| JP2017002448A Pending JP2017105788A (ja) | 2008-06-09 | 2017-01-11 | 体重減少の達成および肥満症の治療のための漸増用量投与計画（ｅｓｃａｌａｔｉｎｇ ｄｏｓｉｎｇ ｒｅｇｉｍｅｎ） |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513646A Pending JP2011522896A (ja) | 2008-06-09 | 2009-06-09 | 低用量トピラメート／フェンテルミン組成物およびその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015102962A Active JP6077053B2 (ja) | 2008-06-09 | 2015-05-20 | 体重減少の達成および肥満症の治療のための漸増用量投与計画（ｅｓｃａｌａｔｉｎｇｄｏｓｉｎｇｒｅｇｉｍｅｎ） |
| JP2015151088A Pending JP2016006085A (ja) | 2008-06-09 | 2015-07-30 | 低用量トピラメート／フェンテルミン組成物およびその使用方法 |
| JP2016246871A Active JP6214750B2 (ja) | 2008-06-09 | 2016-12-20 | 低用量トピラメート／フェンテルミン組成物およびその使用方法 |
| JP2017002448A Pending JP2017105788A (ja) | 2008-06-09 | 2017-01-11 | 体重減少の達成および肥満症の治療のための漸増用量投与計画（ｅｓｃａｌａｔｉｎｇ ｄｏｓｉｎｇ ｒｅｇｉｍｅｎ） |
Country Status (18)
| Country | Link |
|---|---|
| US (11) | US20090304789A1 (enExample) |
| EP (2) | EP2317997B1 (enExample) |
| JP (6) | JP2011522896A (enExample) |
| KR (3) | KR20110044847A (enExample) |
| CN (4) | CN105534921A (enExample) |
| AU (2) | AU2009257573B2 (enExample) |
| BR (2) | BRPI0914985B1 (enExample) |
| CA (2) | CA2727319C (enExample) |
| CL (2) | CL2010001365A1 (enExample) |
| CY (1) | CY1118103T1 (enExample) |
| DK (1) | DK2317997T3 (enExample) |
| ES (1) | ES2606041T3 (enExample) |
| HK (1) | HK1213489A1 (enExample) |
| IL (2) | IL209875A (enExample) |
| MX (2) | MX342684B (enExample) |
| PT (1) | PT2317997T (enExample) |
| WO (2) | WO2009152189A1 (enExample) |
| ZA (2) | ZA201008839B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
| US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| US20090304789A1 (en) | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
| US8580298B2 (en) * | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
| AU2011203970A1 (en) * | 2010-01-07 | 2012-07-12 | Vivus, Inc. | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| BR102012004888A2 (pt) * | 2012-03-05 | 2013-10-22 | Phartrials Pesquisas Farmaceuticas Ltda | Associação de um derivado de sulfamato monossubstituído do monossacarídeo natural d-frutose (topiramato) com um anti-depressivo da classe das fenilcetonas (bupropiona) para tratamento de obesidade e das síndromes plurimetabólicas |
| IN2012DE00826A (enExample) * | 2012-03-21 | 2015-08-21 | Ranbaxy Lab Ltd | |
| CN102579367B (zh) * | 2012-03-23 | 2014-03-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 托吡酯缓释药物组合物、其制备方法及用途 |
| US9457008B2 (en) | 2012-03-23 | 2016-10-04 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Joint product comprising synephrine and topiramate |
| CN103316026B (zh) * | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
| BR102012026555B1 (pt) * | 2012-10-17 | 2022-10-04 | Phartrials Pesquisas Farmacêuticas Ltda | Processo de obtenção e composição de fármaco proveniente do quenodeoxicolato ligado a um derivado de sulfamato monossacarídeo natural d-frutose (topiramato) e a uma fenilcetona (bupropriona) para tratamento da obesidade e das síndromes plurimetabólicas |
| US8652527B1 (en) * | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| US20140294950A1 (en) * | 2013-03-15 | 2014-10-02 | Vivus, Inc. | Methods of treating obesity in responder and non-responder populations |
| US12329902B2 (en) | 2013-08-22 | 2025-06-17 | Sipnose Ltd. | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization |
| US11116914B2 (en) | 2014-11-09 | 2021-09-14 | Sipnose Ltd. | Device and method for aerosolized delivering of substance to a natural orifice of the body |
| DE202013105715U1 (de) | 2013-08-22 | 2014-02-19 | Sipnose Ltd. | Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers |
| US11471618B2 (en) | 2014-11-09 | 2022-10-18 | Sipnose Ltd. | Adjustable dosing delivery and multi sectioned drug compartment |
| US11278682B2 (en) | 2014-11-09 | 2022-03-22 | Sipnose Ltd. | Device and method for aerosolized delivery of substance to a natural orifice of the body |
| US11992604B2 (en) | 2014-11-09 | 2024-05-28 | Sipnose Ltd. | Devices and methods for delivering a substance to a body cavity |
| CA2926321C (en) * | 2013-10-08 | 2023-02-28 | Vivus, Inc. | Methods of preventing progression to type 2 diabetes mellitus |
| US20150157672A1 (en) * | 2013-12-09 | 2015-06-11 | Phytology Labs, Inc. | Kits and methods for sustained weight loss |
| US10278948B1 (en) | 2015-09-03 | 2019-05-07 | Tian Xia | Method for transnasal delivery of anticonvulsant and therapeutic treatments |
| US20170071970A1 (en) * | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
| US10498398B2 (en) * | 2015-10-12 | 2019-12-03 | Walmart Apollo, Llc | Data synthesis using near field communication |
| US20170319540A1 (en) * | 2016-05-06 | 2017-11-09 | Vivus, Inc. | Methods and Compositions for the Treatment of Non-Alcoholic Steatohepatitis |
| EP3897730A1 (en) * | 2018-12-18 | 2021-10-27 | DDP Specialty Electronic Materials US, Inc. | A sustained release composition comprising a methylcellulose |
| CN109908165B (zh) * | 2019-04-26 | 2020-06-09 | 北京大学 | 一种含有雷公藤红素的组合物及其应用 |
| CN109999044B (zh) * | 2019-05-24 | 2020-06-09 | 北京大学 | 一种含有醉茄素a的组合物及其应用 |
| KR102199452B1 (ko) | 2019-10-17 | 2021-01-06 | 안지훈 | 퇴식처리장치 |
| WO2021245605A1 (en) * | 2020-06-04 | 2021-12-09 | Sipnose Ltd | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity |
| US12046341B2 (en) | 2021-10-05 | 2024-07-23 | Bradford Rabin | Methods and systems for electronically adjusting a dosing pattern of a patient undergoing a medical regimen |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| US4895845A (en) * | 1986-09-15 | 1990-01-23 | Seed John C | Method of assisting weight loss |
| US4792569A (en) * | 1987-08-27 | 1988-12-20 | Mcneilab, Inc. | Anticonvulsant phenethyl sulfamates |
| US5273993A (en) * | 1989-06-12 | 1993-12-28 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals |
| US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
| FR2684101B1 (fr) * | 1991-11-22 | 1993-12-31 | Adir Cie | Nouveaux derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
| US5242942A (en) * | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
| US5384327A (en) * | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
| US5543405A (en) * | 1993-10-22 | 1996-08-06 | Keown; Wendy J. | Composition and method for weight reduction and long term management of obesity |
| US5498629A (en) * | 1993-12-23 | 1996-03-12 | Ortho Pharmaceutical Corporation | Anticonvulsant pseudofructopyranose sulfamates |
| US5527788A (en) * | 1994-01-18 | 1996-06-18 | Louisiana State Univ. Medical Center Foundation | Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent |
| US5753694A (en) * | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) |
| US5753693A (en) * | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder |
| US6071537A (en) * | 1996-06-28 | 2000-06-06 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating obesity |
| US5900418A (en) | 1997-02-10 | 1999-05-04 | Synapse Pharmaceuticals International, Inc. | Method for treatment of obesity |
| US5795895A (en) * | 1997-06-13 | 1998-08-18 | Anchors; J. Michael | Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug |
| US5990418A (en) * | 1997-07-29 | 1999-11-23 | International Business Machines Corporation | Hermetic CBGA/CCGA structure with thermal paste cooling |
| US5885616A (en) * | 1997-08-18 | 1999-03-23 | Impax Pharmaceuticals, Inc. | Sustained release drug delivery system suitable for oral administration |
| AU771388B2 (en) * | 1999-01-19 | 2004-03-18 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating cluster headaches |
| WO2000050020A2 (en) * | 1999-02-24 | 2000-08-31 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
| NZ514811A (en) * | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
| MXPA01010221A (es) * | 1999-04-08 | 2002-03-27 | Johnson & Johnson | Derivados anticonvulsivos utiles para disminuir la presion sanguinea. |
| US6420369B1 (en) * | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
| US7659256B2 (en) * | 1999-06-14 | 2010-02-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| WO2000076493A1 (en) * | 1999-06-14 | 2000-12-21 | Thomas Najarian | Combination therapy for effecting weight loss and treating obesity |
| US7056890B2 (en) * | 1999-06-14 | 2006-06-06 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| US7553818B2 (en) * | 1999-06-14 | 2009-06-30 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| US7674776B2 (en) * | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
| US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
| US6759437B2 (en) * | 1999-10-04 | 2004-07-06 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
| WO2002003984A2 (en) * | 2000-07-07 | 2002-01-17 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x |
| US6627653B2 (en) * | 2000-08-02 | 2003-09-30 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
| US20020091114A1 (en) * | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
| JP2004518718A (ja) * | 2000-10-30 | 2004-06-24 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 抗糖尿病薬および抗痙攣薬を含んで成る併用療法 |
| DK1471871T3 (da) * | 2001-02-02 | 2007-09-17 | Ortho Mcneil Pharm Inc | Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin |
| US20030072802A1 (en) * | 2001-10-11 | 2003-04-17 | R.T. Alamo Ventures, Inc. | Sustained release topiramate |
| US6559293B1 (en) * | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
| EP2301537A1 (en) * | 2002-05-17 | 2011-03-30 | Duke University | Zonisamide for the treatment of obesity |
| US20050215552A1 (en) | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
| US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
| KR20060123493A (ko) * | 2003-12-23 | 2006-12-01 | 알자 코포레이션 | 제어된 전달을 위한 약물 조성물의 용해도를 증가시키는방법 및 제형 |
| JP2007517901A (ja) * | 2004-01-13 | 2007-07-05 | デューク・ユニバーシティー | 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物 |
| AU2005271574A1 (en) * | 2004-08-03 | 2006-02-16 | Orexigen Therapeutics, Inc. | Combination of bupropion and a second compound for affecting weight loss |
| BRPI0518241A (pt) * | 2004-11-01 | 2008-04-22 | Amylin Pharmaceuticals Inc | métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
| US7875627B2 (en) * | 2004-12-07 | 2011-01-25 | Abbott Laboratories | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof |
| WO2006063078A2 (en) * | 2004-12-08 | 2006-06-15 | Elan Corporation, Plc | Topiramate pharmaceuticals composition |
| SI1833473T1 (sl) | 2004-12-23 | 2010-01-29 | Arena Pharm Inc | Sestavki modulatorjev 5HT2C receptorjev in postopki uporabe |
| WO2006124506A2 (en) | 2005-05-13 | 2006-11-23 | Abbott Laboratories | Combination and use of drugs |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| WO2007084290A2 (en) | 2006-01-12 | 2007-07-26 | Orexigen Therapeutics, Inc. | Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain |
| WO2008027557A2 (en) * | 2006-08-31 | 2008-03-06 | Spherics, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| FR2907550B1 (fr) | 2006-10-18 | 2009-01-16 | Renault Sas | Ligne de prelevement de gaz circulant dans un conduit de moteur a combustion interne et banc d'essais comportant une telle ligne |
| US8088786B2 (en) | 2006-11-09 | 2012-01-03 | Orexigen Therapeutics, Inc. | Layered pharmaceutical formulations |
| US8298576B2 (en) * | 2006-11-17 | 2012-10-30 | Supernus Pharmaceuticals, Inc. | Sustained-release formulations of topiramate |
| US8071557B2 (en) | 2007-06-13 | 2011-12-06 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors |
| WO2009061436A1 (en) | 2007-11-06 | 2009-05-14 | University Of Florida Research Foundation | Compound for activating 5-ht2c receptors in combination with an amphetamine compound |
| US20090304789A1 (en) * | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
| US8580298B2 (en) * | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
| AU2011203970A1 (en) | 2010-01-07 | 2012-07-12 | Vivus, Inc. | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent |
-
2008
- 2008-06-09 US US12/135,953 patent/US20090304789A1/en not_active Abandoned
-
2009
- 2009-06-09 ES ES09763479.4T patent/ES2606041T3/es active Active
- 2009-06-09 KR KR1020117000417A patent/KR20110044847A/ko not_active Ceased
- 2009-06-09 MX MX2010013505A patent/MX342684B/es active IP Right Grant
- 2009-06-09 BR BRPI0914985-6A patent/BRPI0914985B1/pt active IP Right Grant
- 2009-06-09 JP JP2011513646A patent/JP2011522896A/ja active Pending
- 2009-06-09 CN CN201510977746.2A patent/CN105534921A/zh active Pending
- 2009-06-09 CA CA2727319A patent/CA2727319C/en active Active
- 2009-06-09 KR KR1020147027268A patent/KR20140121491A/ko not_active Ceased
- 2009-06-09 DK DK09763479.4T patent/DK2317997T3/en active
- 2009-06-09 EP EP09763479.4A patent/EP2317997B1/en active Active
- 2009-06-09 EP EP09763480A patent/EP2300002A1/en not_active Ceased
- 2009-06-09 CA CA2727313A patent/CA2727313C/en active Active
- 2009-06-09 MX MX2010013503A patent/MX2010013503A/es active IP Right Grant
- 2009-06-09 US US12/481,548 patent/US8580299B2/en active Active
- 2009-06-09 PT PT97634794T patent/PT2317997T/pt unknown
- 2009-06-09 WO PCT/US2009/046804 patent/WO2009152189A1/en not_active Ceased
- 2009-06-09 CN CN2009801304444A patent/CN102112127A/zh active Pending
- 2009-06-09 AU AU2009257573A patent/AU2009257573B2/en active Active
- 2009-06-09 JP JP2011513647A patent/JP5752595B2/ja active Active
- 2009-06-09 WO PCT/US2009/046805 patent/WO2009152190A1/en not_active Ceased
- 2009-06-09 KR KR1020117000416A patent/KR20110042280A/ko not_active Ceased
- 2009-06-09 AU AU2009257572A patent/AU2009257572C1/en active Active
- 2009-06-09 CN CN201510112539.0A patent/CN104825477A/zh active Pending
- 2009-06-09 CN CN2009801303795A patent/CN102112126A/zh active Pending
- 2009-06-09 BR BRPI0914991A patent/BRPI0914991A2/pt not_active Application Discontinuation
-
2010
- 2010-12-07 CL CL2010001365A patent/CL2010001365A1/es unknown
- 2010-12-07 CL CL2010001366A patent/CL2010001366A1/es unknown
- 2010-12-08 ZA ZA2010/08839A patent/ZA201008839B/en unknown
- 2010-12-08 ZA ZA2010/08840A patent/ZA201008840B/en unknown
- 2010-12-09 IL IL209875A patent/IL209875A/en active IP Right Grant
- 2010-12-09 IL IL209874A patent/IL209874B/en active IP Right Grant
-
2013
- 2013-10-08 US US14/048,416 patent/US8895057B2/en active Active
-
2014
- 2014-09-24 US US14/495,250 patent/US9011906B2/en active Active
-
2015
- 2015-04-06 US US14/679,754 patent/US20150209325A1/en not_active Abandoned
- 2015-05-20 JP JP2015102962A patent/JP6077053B2/ja active Active
- 2015-07-30 JP JP2015151088A patent/JP2016006085A/ja active Pending
- 2015-10-08 US US14/878,235 patent/US20160022630A1/en not_active Abandoned
-
2016
- 2016-02-12 HK HK16101537.0A patent/HK1213489A1/zh unknown
- 2016-05-10 US US15/150,907 patent/US20160250180A1/en not_active Abandoned
- 2016-10-19 CY CY20161101053T patent/CY1118103T1/el unknown
- 2016-12-20 JP JP2016246871A patent/JP6214750B2/ja active Active
-
2017
- 2017-01-11 JP JP2017002448A patent/JP2017105788A/ja active Pending
-
2018
- 2018-12-14 US US16/220,276 patent/US20190350897A1/en not_active Abandoned
-
2020
- 2020-02-20 US US16/796,194 patent/US20200188352A1/en not_active Abandoned
-
2021
- 2021-08-23 US US17/408,881 patent/US20210379013A1/en not_active Abandoned
-
2023
- 2023-03-22 US US18/124,774 patent/US20230233521A1/en active Pending